Members

Dr. Hung-Yi Chen is Assistant Dean, Academic Director (Master of Finance Program) & Asst. Professor at Zhejiang University International Business School. Dr. Chen is the founding academic director of their Master of Finance programme at International Business School, Zhejiang University (QS World Rankings #45). Prior to his career at Zhejiang University, He served as Asia-Pacific Region Manager for Cambridge Centre for Alternative Finance (CCAF), Judge Business School at University of Cambridge. At CCAF, he managed FinTech research activities and expanded international outreach across Asia-Pacific countries. Dr. Chen co-authored six impactful reports published by CCAF to review FinTech development and regulation in the region.

• Neuroimaging methods as brain connectivity (functional and structural)
• Cognitive neuroscience
• Cognitive neuropsychology

i am currently doing research in several topics related to me Industrial and sustainable development practice such as • Fabricating new bioplastic composite materials • Fabricating green corrosion inhibitors • Ergonomics assessment in industrial companies • Green Energy in Construction, LEED, and green building certification • Establishing an integrated sustainable waste management model for agricultural waste • Providing industrial solutions in work in process and inventory models in industrial companies • Assessment of pharmaceutical residues and their removal from water masses • Factors affecting the spread of Covid 19 in Egypt • Impact of COVID 19 on Small and Medium-Sized Enterprises: Case of Plastic Packaging SMEs in Egypt

We are the developer of an innovative technology for the production of a completely new highly effective active substance. These regenerating products are extremely effective in treatment of liver cirrhosis of various etiologies previously officially considered incurable (ascites goes away after 15 days, cirrhosis changes into fibrosis after 30-50 days, the period of complete hepatic regeneration is about 4 months). They are also effective against genital herpes virus (4-6 months), effective against hepatitis of various etiologies, including such as B, C, D ( viral load is reduced by half every 26 days, after a course of therapy, the virus is not detected in the blood, the patient ceases to be a virus carrier), drugs restore the liver in case of fatty hepatosis, pulmonary tuberculosis including MDR TB/ XDR TB (after 26 days an active form of stage 4 changes into stage 2-3 of latent form), lymphosarcoma, fibroma, myoma and pyelonephritis. The drugs prevent diabetic foot gangrene extremities. After the therapy patients no longer need previously recommended heart bypass surgery. The drug restores the function of the pancreas, and gives a complete restoration of long-term erectile dysfunction. The condition of patients with Alzheimer disease, Down's syndrome, encephalopathy, encephalitis and other diseases improves significantly without any side effects. The drugs have a strong antifibrotic effect, they dissolve scars on heart after myocardial infarction. Heart tissue completely regenerates within 6 months. This is only what we have studied so far.  We have strong assumptions that our medications can also effectively affect the activity of the COVID-19 coronavirus, as well as other viruses and infections. We are interested in partners and research of our drugs.